Saudi Chemical Holding Company SJSC
The company's capital structure is characterized by a debt-to-equity ratio of 0.5, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 1.36, suggesting the company can cover its short-term obligations but with limited buffer. Free cash flow of SAR 321.69 million supports operational flexibility, though net cash is negative after subtracting total debt, signaling potential refinancing needs. Profitability metrics show a return on equity (ROE) of 14.07% and a return on assets (ROA) of 5.38%, both exceeding the typical thresholds for the pharmaceuticals industry. The gross profit margin of 12.42% (SAR 855.06 million on SAR 6.88 billion revenue) is in line with industry norms, but the operating margin of 6.87% (SAR 472.60 million) suggests room for improvement in cost control. The company's revenue is distributed across three segments: Explosives, Trading of medicines and medical supplies, and Production of ammonium nitrate. While the financial snapshot does not provide segment-specific revenue figures, the business model implies a diversified exposure to industrial and healthcare markets. The Explosives segment likely contributes to stable demand in infrastructure and defense, while the medical trading segment benefits from healthcare sector growth. Growth trajectory is supported by a positive free cash flow and a capital expenditure of SAR -43.20 million, indicating a focus on maintaining rather than expanding operations. The outlook for the current fiscal year suggests a stable revenue base, with no significant growth drivers identified in the provided data. Risk factors include medium liquidity risk due to the current ratio and negative net cash position. The dilution risk is assessed as low, with no near-term pressure expected. However, the company's reliance on debt financing and the potential for refinancing needs could impact future capital structure. Recent events include the company's continued operations in its core segments, with no major filings or transcripts indicating significant changes in strategy or financial position. The business remains focused on its diversified industrial and commercial activities.
Business. Saudi Chemical Holding Company SJSC operates in the pharmaceuticals and medical research sector, generating revenue through the production and distribution of explosives and derivatives, trading of medicines and medical supplies, and production of ammonium nitrate.
Classification. The company is classified under the Pharmaceuticals & Medical Research industry within the Healthcare economic sector, with a confidence level of 0.92.
- The company maintains a moderate debt-to-equity ratio of 0.5, indicating a balanced capital structure.
- Return on equity of 14.07% and return on assets of 5.38% suggest strong profitability relative to industry norms.
- Free cash flow of SAR 321.69 million provides operational flexibility but is offset by a negative net cash position.
- The company's revenue is spread across three segments, with no segment-specific revenue data provided.
- Liquidity risk is assessed as medium, with a current ratio of 1.36 and a negative net cash position.
- No significant dilution risk is expected in the near term, with low probability of share issuance.
- --
- ## RATIONALES
- Net cash is negative after subtracting total debt.